Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
Date:2/14/2012

the marketplace, or a failure to become or remain profitable; Vanda's expectations regarding trends with respect to its costs and expenses; Vanda's inability to obtain the capital necessary to fund additional research and development activities; Vanda's failure to identify or obtain rights to new products or product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda's ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products or product candidates under its license and sublicense agreements and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely to
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... Aug. 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... the development and commercialization of targeted antiviral therapies, ... Officer, will present live at VirtualInvestorConferences.com on August ... 2015 TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... interactive online event where investors are invited to ...
(Date:8/4/2015)... 4, 2015  Syneron Medical Ltd. (NASDAQ: ELOS ), ... for the three month period ended June 30, 2015. ... 1 Highlights: , Revenue of $73.5 ... , North American product sales grew 45% year-over-year. , ... including 14% product growth in the EMEA region and 25% ...
(Date:8/3/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized leader ... medical physics services and high quality medical consumable accessories, ... fiscal third quarter 2015 after the market close on ... will also host a conference call for investors on ... (10:00 a.m. Eastern Time). Investors may access the live ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... (NASDAQ: VOLC ), a leading developer and ... designed to enhance the treatment of coronary and peripheral ... in the Bank of America Merrill Lynch Health Care ... by Scott Huennekens, president and chief executive officer, will ...
... Mass., May 4, 2011 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has received regulatory ... NxStage System One™ and signed a five-year agreement, the ... Care Group (RHCG), a leading distributor of medical products ...
Cached Medicine Technology:NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand 2NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand 3
(Date:8/4/2015)... York, New York (PRWEB) , ... August 04, 2015 , ... ... this doesn’t begin to describe the customer experience inside Naimie’s Beauty Center in LA. ... help men learn how to look better. , Naimie’s Beauty Center has been a ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale ... finance, announced the closing of a $118 million FHA-insured loan modification refinancing for ... in Smithfield and Clayton, North Carolina. JHSC is a joint venture of ...
(Date:8/4/2015)... ... 04, 2015 , ... Half of consumers are considering a ... increasingly influential in their choice of practitioner, according to new survey data from ... Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical treatments and ratings ...
(Date:8/4/2015)... ... August 04, 2015 , ... Mercy Health (formerly Catholic Health Partners) – a Catholic ... Health: Helping You Be Well videos to preparing high school athletes for fall sports. , ... addresses issues, such as:, , What steps to take to help ...
Breaking Medicine News(10 mins):Health News:MENAJI Shines in Make-Up Mecca for Stars 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4Health News:Mercy Health Video Provides Helpful Information for High School Athletes 2
... Preserving Choice, SACRAMENTO, Calif., Dec. 26 ... non-government HIV testing,program in California, today offered its ... into law yesterday in New Jersey by Acting ... testing of pregnant,women and some newborns for HIV, ...
... Inhibiting the growth of blood vessels that supply ... according to results of a large clinical trial ... in the December 27th issue of the New ... combination with chemotherapy significantly prolongs progression-free survival for ...
... to halting of cancer therapy, report says , , WEDNESDAY, ... for prostate cancer who take baby aspirin to protect ... new research suggests. , Apparently, baby aspirin interacts with ... end result is the man must stop potentially lifesaving ...
... Gentiva Health,Services, Inc. (Nasdaq: GTIV ), the ... announced today that it is,scheduled to present from 1:30 ... the 26th Annual JPMorgan Healthcare Conference in San Francisco., ... via a live audio web cast,which may be accessed ...
... taken more seriously , , WEDNESDAY, Dec. 26 (HealthDay News) ... person,s risk of having a stroke or developing dementia, ... to previous research linking "mini-strokes" to full-fledged strokes, make ... neurology at Johns Hopkins University School of Medicine. , ...
... feature new commercials, print ads and a new website, ... ) today announced that the Company will unveil a new ... 2008. The,focus of the campaign will be celebrity spokeswoman Genie ... just a few months on the,Medifast Program. Francis is best ...
Cached Medicine News:Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 2Health News:AHF Says 'Op-Out' Clause is Crucial to New Jersey Law Requiring HIV Testing of Pregnant Women 3Health News:Bevacizumab found to improve survival for patients with advanced breast cancer 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 2Health News:Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients 3Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 2Health News:Temporary Amnesia, Confusion Raise Stroke, Dementia Risk 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 2Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 3Health News:Medifast, Inc. to Unveil New Advertising Campaign Featuring Genie Francis and New Web Features in Early 2008 4
... of insulin is the C-terminal cleavage product ... to the mature insulin molecule. Although the ... does undergo significant liver or extra-renal metabolism ... half-life than insulin [1]. In addition, C-peptide ...
... a 32 kDa glycoprotein secreted by the ... [1]. The structure of human TSH is ... placental gonadotropins, consisting of an a-subunit which ... and a unique beta-subunit, which confers hormonal ...
... primarily by 5-monodeioination of thyroxine (T4) in ... production occurs at a rate which is ... of T3 from the thyroid gland into ... to 80-100 micrograms/day for T4. In addition, ...
... monomeric protein produced and stored in somatotrophs ... released from the pituitary into the bloodstream ... control of hypothalamic somatostatin (SS) and GH-releasing ... of GH release appears to be regulated ...
Medicine Products: